Our top pick for
Franklin Covey Co is a consulting services business based in the US. Franklin Covey shares (FC) are listed on the NYSE and all prices are listed in US Dollars. Franklin Covey employs 940 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$41.61|
|52-week range||$16.50 - $43.64|
|50-day moving average||$41.45|
|200-day moving average||$35.21|
|Wall St. target price||$45.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.91|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-11)||1.00%|
|1 month (2021-09-17)||2.49%|
|3 months (2021-07-19)||19.67%|
|6 months (2021-04-19)||37.15%|
|1 year (2020-10-16)||123.83%|
|2 years (2019-10-18)||16.49%|
|3 years (2018-10-18)||89.39%|
|5 years (2016-10-18)||130.53%|
Valuing Franklin Covey stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Franklin Covey's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Franklin Covey's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 46x. In other words, Franklin Covey shares trade at around 46x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Franklin Covey's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.126. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Franklin Covey's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Franklin Covey's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $21.2 million.
The EBITDA is a measure of a Franklin Covey's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$204.2 million|
|Operating margin TTM||4.87%|
|Gross profit TTM||$145.4 million|
|Return on assets TTM||3.06%|
|Return on equity TTM||19.48%|
|Market capitalisation||$589.1 million|
TTM: trailing 12 months
There are currently 222,669 Franklin Covey shares held short by investors – that's known as Franklin Covey's "short interest". This figure is 21% down from 281,693 last month.
There are a few different ways that this level of interest in shorting Franklin Covey shares can be evaluated.
Franklin Covey's "short interest ratio" (SIR) is the quantity of Franklin Covey shares currently shorted divided by the average quantity of Franklin Covey shares traded daily (recently around 61681.163434903). Franklin Covey's SIR currently stands at 3.61. In other words for every 100,000 Franklin Covey shares traded daily on the market, roughly 3610 shares are currently held short.
However Franklin Covey's short interest can also be evaluated against the total number of Franklin Covey shares, or, against the total number of tradable Franklin Covey shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Franklin Covey's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Franklin Covey shares in existence, roughly 20 shares are currently held short) or 0.0183% of the tradable shares (for every 100,000 tradable Franklin Covey shares, roughly 18 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Franklin Covey.
Find out more about how you can short Franklin Covey stock.
We're not expecting Franklin Covey to pay a dividend over the next 12 months.
Over the last 12 months, Franklin Covey's shares have ranged in value from as little as $16.5 up to $43.64. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Franklin Covey's is 1.7746. This would suggest that Franklin Covey's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Franklin Covey Co. provides training and consulting services in the areas of execution, sales performance, productivity, customer loyalty, leadership, and educational improvement for organizations and individuals worldwide. The company operates through three segments: Direct Offices, International Licensees, and Education Practice. It also provides a suite of individual-effectiveness and leadership-development training and products. The company serves various private sector, government, and educational institutions in approximately 150 countries and territories. Franklin Covey Co. was founded in 1983 and is headquartered in Salt Lake City, Utah.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.